Gastroenterohepatology Research Center, Shiraz University of Medical Sciences, Shiraz, Iran, Department of Management, Payame Noor University, Tehran, Iran.
Department of Management, Payame Noor University, Tehran, Iran.
Arch Iran Med. 2023 Jan 1;26(1):23-28. doi: 10.34172/aim.2023.04.
The epidemiological burden of chronic diseases and their risk factors is increasing all over the world, especially in developing and low-income countries. Inflammatory bowel disease (IBD) is one of the chronic diseases which has imposed a great financial burden on individuals and the society.
The current study aimed at estimating the economic burden of IBD among 90 patients with IBD who referred to Namazi hospital and Motahari clinic of Shiraz in 2019. The costs to patients were monitored for a year to detect their expenses.
This study is descriptive cross-sectional and from a social perspective. The cost-of-illness method, based on the human capital theory, has been used. Both direct and indirect costs have been estimated using a prevalence approach and bottom-up method. Hospital costs were extracted from patients' records and the accounting system of Namazi Hospital. Outpatient expenses were obtained according to the number of outpatient visits and the average cost of visit were obtained by interviewing patients. Socio-economic status, medical expenses and number of days absent from work were determined using a valid and reliable questionnaire. Assessment of the cost of hospital care was made on the basis of the average daily. Non-medical direct costs such as transportation and residence, etc. were also calculated.
The total annual economic costs of IBD per patient were estimated at 1229.74 USD. Finally, increased use of health care as well as lost productivity leads to increased disease costs.
IBD imposes a substantial economic burden on patients, families and the society. Establishing a correct diagnosis early, management of IBD worsening, and appropriate treatment can reduce the costs of treatment and lost production to some extent. Therefore, policymakers should take this into consideration and according to available health resources, provide services and facilities for the prevention and treatment of the disease.
慢性疾病及其危险因素的流行病学负担在全球范围内不断增加，尤其是在发展中国家和低收入国家。炎症性肠病（IBD）是一种慢性疾病，它给个人和社会带来了巨大的经济负担。
本研究旨在估计 2019 年在纳马齐医院和设拉子莫塔哈里诊所就诊的 90 名 IBD 患者的 IBD 经济负担。监测了患者一年的费用，以确定他们的支出。
这是一项描述性的横断面研究，从社会角度出发。采用基于人力资本理论的疾病成本法，采用患病率方法和自下而上的方法估计直接和间接成本。从患者的病历和纳马齐医院的会计系统中提取医院费用。根据就诊次数和每位患者的平均就诊费用，从门诊费用中获取门诊费用。使用有效和可靠的问卷确定社会经济地位、医疗费用和缺勤天数。根据平均日费用评估医院护理费用。还计算了非医疗直接费用，如交通和住宿等。
每位患者的 IBD 年总经济成本估计为 1229.74 美元。最终，对医疗保健的更多使用以及生产力的丧失导致疾病成本的增加。
IBD 给患者、家庭和社会带来了巨大的经济负担。早期做出正确诊断、管理 IBD 恶化以及进行适当的治疗可以在一定程度上降低治疗成本和生产力损失。因此，政策制定者应该考虑到这一点，并根据现有的卫生资源，为疾病的预防和治疗提供服务和设施。
